From Wikipedia, the free encyclopedia

IGF1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases IGF1, IGF-I, IGF1A, IGFI, MGF, insulin like growth factor 1, IGF
External IDs OMIM: 147440 MGI: 96432 HomoloGene: 515 GeneCards: IGF1
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000618
NM_001111283
NM_001111284
NM_001111285

RefSeq (protein)

NP_000609
NP_001104753
NP_001104754
NP_001104755

NP_001104744
NP_001104745
NP_001104746
NP_001300939
NP_034642

Location (UCSC) Chr 12: 102.4 – 102.48 Mb Chr 10: 87.69 – 87.77 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults. [5]

In the 1950s IGF-1 was called " sulfation factor" because it stimulated sulfation of cartilage in vitro, [6] and in the 1970s due to its effects it was termed "nonsuppressible insulin-like activity" (NSILA). [7]

IGF-1 is a protein that in humans is encoded by the IGF1 gene. [8] [9] IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7,649 daltons. [10] In dogs, an ancient mutation in IGF1 is the primary cause of the toy phenotype. [11]

IGF-1 is produced primarily by the liver. Production is stimulated by growth hormone (GH). Most of IGF-1 is bound to one of 6 binding proteins (IGF-BP). IGFBP-1 is regulated by insulin. IGF-1 is produced throughout life; the highest rates of IGF-1 production occur during the pubertal growth spurt. [12] The lowest levels occur in infancy and old age. [13] [14]

A synthetic analog of IGF-1, mecasermin, is used for the treatment of growth failure in children with severe IGF-1 deficiency. [15]

Cyclic glycine-proline (cGP) is a metabolite of hormone insulin-like growth factor-1 (IGF-1). It has a cyclic structure, lipophilic nature, and is enzymatically stable which makes it a more favourable candidate for manipulating the binding-release process between IGF-1 and its binding protein, thereby normalising IGF-1 function. [16]

Synthesis and circulation

The polypeptide hormone IGF-1 is synthesized primarily in the liver upon stimulation by growth hormone (GH). It is a key mediator of anabolic activities in numerous tissues and cells, such as growth hormone-stimulated growth, metabolism and protein translation. [17] Due to its participation in the GH-IGF-1 axis it contributes among other things to the maintenance of muscle strength, muscle mass, development of the skeleton and is a key factor in brain, eye and lung development during fetal development. [18]

A deficiency of IGF-1 is associated with the increased risks of insulin resistance, glucose intolerance, diabetes type 2, as well as cardiovascular morbidity and mortality. [17] [19] Studies have shown the importance of the GH-IGF-1 axis in directing development and growth, where mice with a IGF-1 deficiency had a reduced body- and tissue mass. Mice with an excessive expression of IGF-1 had an increased mass. [19]

The levels of IGF-1 in the body vary throughout life, depending on age, where peaks of the hormone is generally observed during puberty and the postnatal period. After puberty, when entering the third decade of life, there is a rapid decrease in IGF-1 levels due to the actions of GH. Between the third and eight decade of life, the IGF-1 levels decrease gradually, but unrelated to functional decline. [18] However, protein intake is proven to increase IGF-1 levels. [20]

3-d model of IGF-1

Mechanism of action

IGF-1 is a primary mediator of the effects of growth hormone (GH). Growth hormone is made in the anterior pituitary gland, is released into the blood stream, and then stimulates the liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body, especially skeletal muscle, cartilage, bone, liver, kidney, nerve, skin, hematopoietic, and lung cells. In addition to the insulin-like effects, IGF-1 can also regulate cellular DNA synthesis. [21]

IGF-1 binds to at least two cell surface receptor tyrosine kinases: the IGF-1 receptor (IGF1R), and the insulin receptor. Its primary action is mediated by binding to its specific receptor, IGF1R, which is present on the surface of many cell types in many tissues. Binding to the IGF1R initiates intracellular signaling. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death . [22] [23] The IGF-1 receptor and insuline receptor are two closely related members of a transmembrane tetrameric tyrosine kinase receptor family. They control vital brain functions, such as survival, growth, energy metabolism, longevity, neuroprotection and neuroregeneration. [24]

IGF-1 binds and activates its own receptor, IGF-1R, through the cell surface expression of Receptor Tyrosine Kinase's (RTK's), and further signals through multiple intracellular transduction cascades. IGF-1R is the critical role-playing inducer in modulating the metabolic effects of IGF-1 for cellular senescence and survival. At a localized target cell, IGF-1R elicits the mediation of paracrine activity. After its activation the initiation of intracellular signaling occurs inducing a magnitude of signaling pathways. An important mechanistic pathway involved in mediating a cascade affect regulated by phosphatidylinositol-3 kinase ( PI3K) and its downstream partner, mTOR (mammalian Target of Rapamycin). Rapamycin binds with the enzyme FKBPP12 to inhibit the mTORC1 complex. mTORC2 remains unaffected and responds by up-regulating AKT, driving signals through the inhibited mTORC1. Phosphorylation of Eukaryotic translation initiation factor 4E ( EIF4E) by mTOR suppresses the capacity of Eukaryotic translation initiation factor 4E-binding protein 1 ( EIF4EBP1) to inhibit EIF4E and slow metabolism. [25] [26] A mutation in the signaling pathway PI3K-AKT-mTOR is a big factor in the formation of tumors found predominantly on skin, internal organs, and secondary lymph nodes (Kaposi sarcoma). [26]

Metabolic effects

As a major growth factor, IGF-1 is responsible for stimulating growth of all cell types, and causing significant metabolic effects. [27] One important metabolic effect of IGF-1 is its ability to signal cells that sufficient nutrients are available for cells to undergo hypertrophy and cell division. [28] These signals also enable IGF-1 to inhibit cell apoptosis and increase the production of cellular proteins. [28] IGF-1 receptors are ubiquitous, which allows for metabolic changes caused by IGF-1 to occur in all cell types. [27] IGF-1's metabolic effects are far-reaching and can coordinate protein, carbohydrate, and fat metabolism in a variety of different cell types. [27] The regulation of IGF-1's metabolic effects on target tissues is also coordinated with other hormones such as growth hormone and insulin. [29]

Related growth factors

IGF-1 exists within the insulin/insulin-like growth factor (IGF) signaling system. The system consists of three ligands ( insulin, IGF-1 and IGF-2, 2 tyrosine kinase receptors ( insulin receptor and IGF-1R receptor) and six ligand binding proteins (IGFBP 1-6). [30] It plays an essential role in proliferation, survival, regulation of cell growth and affects almost every organ system in the body. [31]

Similarly to IGF-1, IGF-2 is mainly produced in the liver. After release into circulation it stimulates growth and cell proliferation. IGF-2 is thought to be a fetal growth factor, as it is essential for a normal embryonic development and is highly expressed in embryonic and neonatal tissues. [32]

A splice variant of IGF-1 sharing an identical mature region, but with a different E domain is known as mechano-growth factor (MGF). [33]

Disorders

Laron syndrome

Patients with severe primary insulin-like growth factor-1 deficiency (IGFD), called Laron syndrome (LS) or Laron dwarfism, may be treated with Mecasermin (brand name Increlex). This is a synthetic analog of IGF-1 which is approved for the treatment of growth failure. [34]

Laron syndrome does not respond at all to growth hormone treatment due to a lack of GH receptors. The FDA has grouped these diseases into a disorder called severe primary IGF deficiency. Patients with severe primary IGFD typically present with normal to high GH levels, height below 3 standard deviations (SD), and IGF-1 levels below 3 SD. [35] Severe primary IGFD includes patients with mutations in the GH receptor, post-receptor mutations or IGF mutations, as previously described. As a result, these patients cannot be expected to respond to GH treatment. [36]

People with Laron syndrome have very low rates of both cancer and diabetes. [37]

Acromegaly

Acromegaly is a syndrome that results in the anterior pituitary gland producing excess growth hormone (GH). A number of disorders may increase the pituitary's GH output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell ( somatotrophs). It leads to anatomical changes and metabolic dysfunction caused by both an elevated GH and elevated IGF-1 levels. [38]

High level of IGF-1 in acromegaly is related to an increased risk of some cancers, particularly colon cancer and thyroid cancer. [39]

Use as a diagnostic test

IGF-1 levels can be analyzed and used by physicians as a screening test for growth hormone deficiency, acromegaly and gigantism. [35] However IGF-1 was proved to be a bad diagnostic screening test for growth hormone deficiency (GHD). Therefore, IGF-1 should not be used alone as a screening test for GHD. [40]

The ratio of IGF-1 and insulin-like growth factor 1 binding protein-3 (IGFBP-3) can be analyzed and used as a diagnostic tool for growth-hormone related disorders. [41]

Interpretation of IGF-1 levels is complicated by the wide normal ranges, and marked variations by age, sex, and pubertal stage. Clinically significant conditions and changes may be masked by the wide normal ranges. Sequential measurement over time is often useful for the management of several types of pituitary disease, undernutrition, and growth problems. [42]

Causes of elevated IGF-1 levels

Health effects

Cancer

Several studies have shown associations between high levels of IGF-1 and an increased risk of tumor development. With an increase in serum IGF-1 levels of 100 ng/ml, there was a corresponding increase in the risk of colorectal cancer with 69%. High levels of IGF-1 were also associated with a 65% risk increase in breast cancer, 49% increase in prostate cancer and 106% in lung cancer. [48]

It has been suggested that consumption of IGF-1 in dairy products could increase cancer risk, particularly prostate cancer. [49] [50] However, a 2018 review by the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC) concluded that there is "insufficient evidence to draw any firm conclusions as to whether exposure to dietary IGF-1 is associated with an increased incidence of cancer in consumers". [50] Certain dairy processes such as fermentation are known to significantly decrease IGF-1 concentrations. [51]

A mutation in the signaling pathway PI3K-AKT-mTOR is a factor in the formation of tumors found predominantly on skin, internal organs, and secondary lymph nodes (Kaposi sarcoma). [52]

Diabetes

Low IGF-1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance. [53] On the other hand, a high IGF-1 bioavailability in diabetes patients may delay or prevent the inception of diabetes-associated complications. A normal functioning IGF-1 mechanism reduces the occurrence of diabetes complications associated with lower IGF-1 levels, as it improves impaired small blood vessel function. [54]

Mortality

A 2022 review found that both high and low levels of IGF‐1 increase mortality risk, whilst a mid‐range (120–160 ng/ml) is associated with the lowest mortality. [48]

Other

Increased IGF-1 levels are associated with a lower risk of cardiovascular disease and ischaemic stroke. [55] [56] [57]

Clinical trials

Mecasermin

Mecasermin is a complex consisting of recombinant human IGF-1 and recombinant human IGF-binding protein-3. [58] The complex is used for the long-term treatment in children with growth failure, where they suffer from severe IGF-1 deficiency unresponsive to GH. Children with growth failure were given 0,12 mg/kg subcutaneous mecasermin two times a day over a period with a mean duration of 4,4 years (range: 0,04-12,5 years). During the first year of treatment the height velocity of the children increased from a mean of 2,8 cm/year at baseline to a mean of 8,0 cm/year. The mean growth velocities continued to remain above baseline for up to 8 years. [59]

Mecasermin therapy is also shown to be beneficial with other conditions including diabetes mellitus and anorexia nervosa. [59]

rhIGF-1

Several companies have evaluated administering recombinant human IGF-1 (rhIGF-1) in clinical trials for type 1 diabetes. These patients, despite having increased GH secretion, have low levels of circulating IGF-1 and therefore may benefit from rhIGF-1 therapy. [60] Results shows that a rhIGF-1 therapy two times a day in adults with type 1 diabetes increased the circulating IGF-1. This was with a reciprocal decrease in IGF-2 and an elevation of IGFBP-2. [60]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000017427 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000020053 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Tahimic CG, Wang Y, Bikle DD (2013). "Anabolic effects of IGF-1 signaling on the skeleton". Frontiers in Endocrinology. 4: 6. doi: 10.3389/fendo.2013.00006. PMC  3563099. PMID  23382729.
  6. ^ Salmon WD, Daughaday WH (June 1957). "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro". The Journal of Laboratory and Clinical Medicine. 49 (6): 825–836. PMID  13429201.
  7. ^ Meuli C, Zapf J, Froesch ER (April 1978). "NSILA-carrier protein abolishes the action of nonsuppressible insulin-like activity (NSILA-S) on perfused rat heart". Diabetologia. 14 (4): 255–259. doi: 10.1007/BF01219425. PMID  640301.
  8. ^ Höppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, Jansen M, Kittur SD, Antonarakis SE, et al. (1985). "The human gene encoding insulin-like growth factor I is located on chromosome 12". Human Genetics. 69 (2): 157–160. doi: 10.1007/BF00293288. PMID  2982726. S2CID  5825276.
  9. ^ Jansen M, van Schaik FM, Ricker AT, Bullock B, Woods DE, Gabbay KH, et al. (1983). "Sequence of cDNA encoding human insulin-like growth factor I precursor". Nature. 306 (5943): 609–611. Bibcode: 1983Natur.306..609J. doi: 10.1038/306609a0. PMID  6358902. S2CID  4336584.
  10. ^ Rinderknecht E, Humbel RE (April 1978). "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin". The Journal of Biological Chemistry. 253 (8): 2769–2776. doi: 10.1016/S0021-9258(17)40889-1. PMID  632300.
  11. ^ Callaway E (February 2022). "Big dog, little dog: mutation explains range of canine sizes". Nature. 602 (7895): 18. Bibcode: 2022Natur.602...18C. doi: 10.1038/d41586-022-00209-0. PMID  35087254. S2CID  246359754.
  12. ^ Decourtye L, Mire E, Clemessy M, Heurtier V, Ledent T, Robinson IC, et al. (2017). "IGF-1 Induces GHRH Neuronal Axon Elongation during Early Postnatal Life in Mice". PLOS ONE. 12 (1): e0170083. Bibcode: 2017PLoSO..1270083D. doi: 10.1371/journal.pone.0170083. PMC  5226784. PMID  28076448.
  13. ^ Suwa S, Katsumata N, Maesaka H, Tokuhiro E, Yokoya S (December 1988). "Serum insulin-like growth factor I (somatomedin-C) level in normal subjects from infancy to adulthood, pituitary dwarfs and normal variant short children". Endocrinologia Japonica. 35 (6): 857–864. doi: 10.1507/endocrj1954.35.857. PMID  3250861. S2CID  6965802.
  14. ^ Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson BA (September 1994). "Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin". Clinical Endocrinology. 41 (3): 351–357. doi: 10.1111/j.1365-2265.1994.tb02556.x. PMID  7955442. S2CID  24346368.
  15. ^ Keating GM (2008). "Mecasermin". BioDrugs. 22 (3): 177–188. doi: 10.2165/00063030-200822030-00004. PMID  18481900.
  16. ^ Guan J, Li F, Kang D, Anderson T, Pitcher T, Dalrymple-Alford J, Shorten P, Singh-Mallah G (19 January 2023). "Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions". Molecules. 28 (3): 1021. doi: 10.3390/molecules28031021. ISSN  1420-3049. PMC  9919809. PMID  36770687.
  17. ^ a b Larsson SC, Michaëlsson K, Burgess S (September 2020). "IGF-1 and cardiometabolic diseases: a Mendelian randomisation study". Diabetologia. 63 (9): 1775–1782. doi: 10.1007/s00125-020-05190-9. PMC  7406523. PMID  32548700.
  18. ^ a b Guo J, Xie J, Zhou B, Găman MA, Kord-Varkaneh H, Clark CC, et al. (1 April 2020). "The influence of zinc supplementation on IGF-1 levels in humans: A systematic review and meta-analysis". Journal of King Saud University - Science. 32 (3): 1824–1830. doi: 10.1016/j.jksus.2020.01.018. ISSN  1018-3647.
  19. ^ a b Xie W, Tang Z, Guo Y, Zhang C, Zhang H, Han Y, et al. (September 2019). "Seasonal expressions of growth hormone receptor, insulin-like growth factor 1 and insulin-like growth factor 1 receptor in the scented glands of the muskrats (Ondatra zibethicus)". General and Comparative Endocrinology. 281: 58–66. doi: 10.1016/j.ygcen.2019.05.014. PMID  31121166. S2CID  163168020.
  20. ^ Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, et al. (March 2014). "Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population". Cell Metabolism. 19 (3): 407–417. doi: 10.1016/j.cmet.2014.02.006. PMC  3988204. PMID  24606898.
  21. ^ Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. (September 2002). "Circulating levels of IGF-1 directly regulate bone growth and density". The Journal of Clinical Investigation. 110 (6): 771–781. doi: 10.1172/JCI15463. PMC  151128. PMID  12235108.
  22. ^ Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. (October 1999). "Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis". Molecular and Cellular Biology. 19 (10): 7203–7215. doi: 10.1128/mcb.19.10.7203. PMC  84713. PMID  10490655.
  23. ^ Juin P, Hueber AO, Littlewood T, Evan G (June 1999). "c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release". Genes & Development. 13 (11): 1367–1381. doi: 10.1101/gad.13.11.1367. PMC  316765. PMID  10364155.
  24. ^ Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (February 2010). "Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling". Neurobiology of Aging. 31 (2): 224–243. doi: 10.1016/j.neurobiolaging.2008.04.002. PMID  18479783. S2CID  14265087.
  25. ^ Martin D, Nguyen Q, Molinolo A, Gutkind JS (May 2014). "Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene". Oncogene. 33 (18): 2405–2412. doi: 10.1038/onc.2013.193. PMID  23708663.
  26. ^ a b Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, et al. (April 2019). "4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer". Cancer Research. 79 (7): 1438–1450. doi: 10.1158/0008-5472.CAN-18-1220. PMC  6445709. PMID  30894372.
  27. ^ a b c Clemmons DR (June 2012). "Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes". Endocrinology and Metabolism Clinics of North America. 41 (2): 425–43, vii–viii. doi: 10.1016/j.ecl.2012.04.017. PMC  3374394. PMID  22682639.
  28. ^ a b Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, Barton ER (November 2015). "Role of IGF-I signaling in muscle bone interactions". Bone. 80: 79–88. doi: 10.1016/j.bone.2015.04.036. PMC  4600536. PMID  26453498.
  29. ^ Clemmons DR (January 2004). "The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity". The Journal of Clinical Investigation. 113 (1): 25–27. doi: 10.1172/JCI200420660. PMC  300772. PMID  14702105.
  30. ^ García-Mato Á, Cervantes B, Murillo-Cuesta S, Rodríguez-de la Rosa L, Varela-Nieto I (September 2021). "Insulin-like Growth Factor 1 Signaling in Mammalian Hearing". Genes. 12 (10): 1553. doi: 10.3390/genes12101553. PMC  8535591. PMID  34680948.
  31. ^ Annunziata M, Granata R, Ghigo E (March 2011). "The IGF system". Acta Diabetologica. 48 (1): 1–9. doi: 10.1007/s00592-010-0227-z. PMID  21042815. S2CID  24843614.
  32. ^ Winston BW, Ni A, Aurora RC (2006). "Insulin-like Growth Factors". In Laurent GJ, Shapiro SD (eds.). Encyclopedia of Respiratory Medicine. pp. 339–346. doi: 10.1016/B0-12-370879-6/00453-1. ISBN  978-0-12-370879-3. GF-II appears to be essential for normal embryonic development and, as such, IGF-II is thought to be a fetal growth factor. IGF-II is highly expressed in embryonic and neonatal tissues and promotes proliferation of many cell types primarily of fetal origin.
  33. ^ Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, et al. (February 2008). "Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction". Heart, Lung & Circulation. 17 (1): 33–39. doi: 10.1016/j.hlc.2007.04.013. PMID  17581790.
  34. ^ Rosenbloom AL (August 2007). "The role of recombinant insulin-like growth factor I in the treatment of the short child". Current Opinion in Pediatrics. 19 (4): 458–464. doi: 10.1097/MOP.0b013e3282094126. PMID  17630612. S2CID  23165648.
  35. ^ a b Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. (December 2014). "Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation". The New England Journal of Medicine. 371 (25): 2363–2374. doi: 10.1056/NEJMoa1408028. PMC  4291174. PMID  25470569.
  36. ^ Cohen J, Blethen S, Kuntze J, Smith SL, Lomax KG, Mathew PM (March 2014). "Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management". Drugs in R&D. 14 (1): 25–29. doi: 10.1007/s40268-014-0039-7. PMC  3964293. PMID  24639006.
  37. ^ Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. (February 2011). "Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans". Science Translational Medicine. 3 (70): 70ra13. doi: 10.1126/scitranslmed.3001845. PMC  3357623. PMID  21325617.
  38. ^ a b Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. (April 2014). "Expert consensus document: A consensus on the medical treatment of acromegaly". Nature Reviews. Endocrinology. 10 (4): 243–248. doi: 10.1038/nrendo.2014.21. PMID  24566817.
  39. ^ AlDallal S (August 2018). "Acromegaly: a challenging condition to diagnose". review. International Journal of General Medicine. 11: 337–343. doi: 10.2147/IJGM.S169611. PMC  6112775. PMID  30197531.
  40. ^ Iwayama H, Kitagawa S, Sada J, Miyamoto R, Hayakawa T, Kuroyanagi Y, Muto T, Kurahashi H, Ohashi W, Takagi J, Okumura A (9 August 2021). "Insulin-like growth factor-1 level is a poor diagnostic indicator of growth hormone deficiency". Scientific Reports. 11 (1): 16159. Bibcode: 2021NatSR..1116159I. doi: 10.1038/s41598-021-95632-0. ISSN  2045-2322. PMC  8352887. PMID  34373538.
  41. ^ Haj-Ahmad LM, Mahmoud MM, Sweis NW, Bsisu I, Alghrabli AM, Ibrahim AM, Zayed AA (17 October 2022). "Serum IGF-1 to IGFBP-3 Molar Ratio: A Promising Diagnostic Tool for Growth Hormone Deficiency in Children". The Journal of Clinical Endocrinology & Metabolism. 108 (4): 986–994. doi: 10.1210/clinem/dgac609. ISSN  0021-972X. PMID  36251796.
  42. ^ Postma MR, van Beek AP, van der Klauw MM, Lentjes EG, Muller Kobold AC (March 2024). "IGF-1 as screening tool for acromegaly and adult-onset growth hormone deficiency in the Netherlands". Clinical Endocrinology. 100 (3): 260–268. doi: 10.1111/cen.15000. PMID  38044875.
  43. ^ Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, et al. (March 2014). "Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population". primary. Cell Metabolism. 19 (3): 407–417. doi: 10.1016/j.cmet.2014.02.006. PMC  3988204. PMID  24606898.
  44. ^ Melnik BC, John SM, Schmitz G (June 2011). "Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome". primary. Nutrition & Metabolism. 8: 41. doi: 10.1186/1743-7075-8-41. PMC  3141390. PMID  21699736.
  45. ^ Imran SA, Pelkey M, Clarke DB, Clayton D, Trainer P, Ezzat S (2010). "Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall". primary. International Journal of Endocrinology. 2010: 1–4. doi: 10.1155/2010/370692. PMC  2939391. PMID  20862389.
  46. ^ a b c Freda PU (August 2009). "Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?". review. Clinical Endocrinology. 71 (2): 166–170. doi: 10.1111/j.1365-2265.2009.03556.x. PMC  3654652. PMID  19226264.
  47. ^ Phillips JD, Yeldandi A, Blum M, de Hoyos A (October 2009). "Bronchial carcinoid secreting insulin-like growth factor-1 with acromegalic features". primary. The Annals of Thoracic Surgery. 88 (4): 1350–1352. doi: 10.1016/j.athoracsur.2009.02.042. PMID  19766843.
  48. ^ a b Rahmani J, Montesanto A, Giovannucci E, Zand H, Barati M, Kopchick JJ, et al. (February 2022). "Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis". Aging Cell. 21 (2): e13540. doi: 10.1111/acel.13540. PMC  8844108. PMID  35048526.
  49. ^ Harrison S, Lennon R, Holly J, Higgins JP, Gardner M, Perks C, et al. (June 2017). "Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis". Cancer Causes & Control. 28 (6): 497–528. doi: 10.1007/s10552-017-0883-1. PMC  5400803. PMID  28361446.
  50. ^ a b "Statement on possible carcinogenic hazard to consumers from insulin-like growth factor-1 (IGF-1) in the diet" (PDF). assets.publishing.service.gov.uk. Retrieved 4 February 2023.
  51. ^ Meyer Z, Höflich C, Wirthgen E, Olm S, Hammon HM, Hoeflich A (August 2017). "Analysis of the IGF-system in milk from farm animals - Occurrence, regulation, and biomarker potential". Growth Hormone & IGF Research. 35: 1–7. doi: 10.1016/j.ghir.2017.05.004. PMID  28544872.
  52. ^ Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, et al. (April 2019). "4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer". Cancer Research. 79 (7): 1438–1450. doi: 10.1158/0008-5472.CAN-18-1220. PMC  6445709. PMID  30894372.
  53. ^ Biadgo B, Tamir W, Ambachew S (1 May 2021). "Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review". The Review of Diabetic Studies. 16 (1): 24–34. doi: 10.1900/RDS.2020.16.24. PMC  9380093. PMID  33905470.
  54. ^ Biadgo B, Tamir W, Ambachew S (1 May 2021). "Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review". The Review of Diabetic Studies. 16 (1): 24–34. doi: 10.1900/RDS.2020.16.24. ISSN  1613-6071. PMC  9380093. PMID  33905470.
  55. ^ Higashi Y, Gautam S, Delafontaine P, Sukhanov S (April 2019). "IGF-1 and cardiovascular disease". Growth Hormone & IGF Research. 45: 6–16. doi: 10.1016/j.ghir.2019.01.002. PMC  6504961. PMID  30735831.
  56. ^ Li T, Zhao Y, Yang X, Feng Y, Li Y, Wu Y, et al. (December 2022). "Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose-response meta-analysis of cohort studies". Journal of Endocrinological Investigation. 45 (12): 2221–2231. doi: 10.1007/s40618-022-01819-1. PMID  35596917. S2CID  248924624.
  57. ^ Li Y, Yang W, Li J, Zhang Y, Zhang L, Chen S, et al. (June 2022). "Relationship between serum insulin-like growth factor 1 levels and ischaemic stroke: a systematic review and meta-analysis". BMJ Open. 12 (6): e045776. doi: 10.1136/bmjopen-2020-045776. PMC  9204407. PMID  35705353.
  58. ^ Keegan MT (2019). "Endocrine Pharmacology". In Hemmings Jr HC, Egan TD (eds.). Pharmacology and Physiology for Anesthesia (2nd ed.). pp. 708–731. doi: 10.1016/B978-0-323-48110-6.00036-3. ISBN  978-0-323-48110-6. S2CID  262107214. Mecasermin is a complex of recombinant human IGF-1 and recombinant human IGF-binding protein-3 (rhIGFBP-3) used to treat children with severe IGF-1 deficiency unresponsive to GH.
  59. ^ a b Keating GM (2008). "Mecasermin". BioDrugs. 22 (3): 177–188. doi: 10.2165/00063030-200822030-00004. PMID  18481900.
  60. ^ a b Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sönksen PH, Russell-Jones DL (December 1998). "Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment". Clinical Endocrinology. 49 (6): 739–746. doi: 10.1046/j.1365-2265.1998.00600.x. PMID  10209561. S2CID  20727527.

External links